Brunner Lab
Publications

Publications

Petri, M; Aringer, M; Ayoub, I; Almaani, S; Brunner, H; Dall’Era, M; Jiang, M; Furie, R; Greco, J; Goldblatt, F; et al. Systemic Lupus Erythematosus. A Clinician's Pearls & Myths in Rheumatology. 2023.

Smitherman, EA; Chahine, RA; Lewandowski, LB; Rahman, AF; Wenderfer, SE; Curtis, JR; Hersh, AO; Abel, N; Abulaban, K; Adams, A; et al. Childhood-Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short-Term Kidney Status and Variation in Care. Arthritis Care and Research. 2023.

Cody, EM; Wenderfer, SE; Sullivan, KE; Kim, AH J; Figg, W; Ghumman, H; Qiu, T; Huang, B; Devarajan, P; Brunner, HI. Urine biomarker score captures response to induction therapy with lupus nephritis. Pediatric Nephrology. 2023.

Ruperto, N; Lovell, DJ; Berman, A; Ávila-Zapata, F; Horneff, G; Alessio, M; Becker, ML; Belot, A; Burgos-Vargas, R; Gamir, ML; et al. Patient-Reported Outcomes Among Patients Ages Two to Seventeen Years With Polyarticular-Course Juvenile Idiopathic Arthritis Treated With Subcutaneous Abatacept: Two-Year Results From an International Phase III Study. Arthritis Care and Research. 2023.

Brunner, HI; Foeldvari, I; Alexeeva, E; Ayaz, NA; Calvo Penades, I; Kasapcopur, O; Chasnyk, VG; Hufnagel, M; Zuber, Z; Schulert, G; et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Annals of the Rheumatic Diseases. 2023; 82:154-160.

Smitherman, EA; Chahine, RA; Bitencourt, N; Rahman, AK M F; Lawson, EF; Chang, JC; Abel, N; Abulaban, K; Adams, A; Adams, M; et al. Patient-Reported Outcomes Among Transition-Age Young Adults With Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Journal of Rheumatology. 2023; 50:98-106.

Borgia, RE; Gurka, MJ; Filipp, SL; Elder, M; Cardel, M; Shiff, NJ; Abel, N; Abulaban, K; Adams, A; Adams, M; et al. Race, ethnicity and patient-reported outcomes in childhood-onset systemic lupus erythematosus. Clinical and Experimental Rheumatology. 2023; 41:186-194.

Johnson, SR; Gladman, DD; Brunner, HI; Isenberg, D; Clarke, AE; Barber, MR W; Arnaud, L; Fortin, PR; Mosca, M; Voskuyl, A; et al. Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research. 2022.

Martini, A; Lovell, DJ; Albani, S; Brunner, HI; Hyrich, KL; Thompson, SD; Ruperto, N. Juvenile idiopathic arthritis. . 2022.

Soulsby, WD; Balmuri, N; Cooley, V; Gerber, LM; Lawson, E; Goodman, S; Onel, K; Mehta, B; Abel, N; Abulaban, K; et al. Social determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology. 2022; 20.

Miraldi Utz, V; Angeles-Han, ST; Mwase, N; Cassedy, A; Hennard, T; Lovell, DJ; Lopper, S; Brunner, HI; Dosunmu, EO; Grom, AA; et al. Alternative Biologic Therapy in Children Failing Conventional TNFα Inhibitors for Refractory, Noninfectious, Chronic Anterior Uveitis. American Journal of Ophthalmology. 2022; 244:183-195.

Neely, J; Ardalan, K; Huber, A; Kim, S; Abel, N; Abulaban, K; Adams, A; Adams, M; Agbayani, R; Aiello, J; et al. Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry. Pediatric Rheumatology. 2022; 20.

Hahn, T; Daymont, C; Groh, B; Hays, K; Bingham, CA; Scalzi, L; Abel, N; Abulaban, K; Adams, A; Adams, M; et al. Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology. 2022; 20.

de Amorim, JC; Kishimoto, ST; Elorza, CL C; Cavaletti, FA; Marini, R; Silva, CA; Saad-Magalhães, C; Fernandes, PT; Brunner, HI; Appenzeller, S. Cross-cultural adaptation and initial validation of the Brazilian-Portuguese version of the pediatric automated neuropsychological assessment metrics. Frontiers in Psychology. 2022; 13.

Ogbu, EA; Brunner, HI. Treatment Guidelines in Pediatric Rheumatic Diseases. Rheumatic Disease Clinics of North America. 2022; 48:725-746.

Cody, EM; Rose, JE; Huang, B; Qiu, T; Brunner, HI; Devarajan, P. Stability of novel urinary biomarkers used for lupus nephritis. Frontiers in Pediatrics. 2022; 10.

Weiss, PF; Fuhlbrigge, RC; von Scheven, E; Lovell, DJ; Colbert, RA; Brunner, HI. Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis. Arthritis Care and Research. 2022; 74:1058-1064.

Gerss, J; Tedy, M; Klein, A; Horneff, G; Miranda-Garcia, M; Kessel, C; Holzinger, D; Stanevica, V; Swart, JF; Cabral, DA; et al. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Annals of the Rheumatic Diseases. 2022; 81:990-997.

Ruperto, N; Brunner, H; Berman, A; Avila Zapata, F; Horneff, G; Wagner-Weiner, L; Belot, A; Burgos-Vargas, R; Gámir Gámir, ML; Goldenstein-Schainberg, C; et al. POS0340 PREDICTORS OF CLINICAL RESPONSE TO ABATACEPT IN CHILDREN WITH POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS. Annals of the Rheumatic Diseases. 2022; 81:422.2-42423.

Ruperto, N; Chertok, E; Dehoorne, J; Horneff, G; Kallinich, T; Louw, I; Compeyrot-Lacassagne, S; Lauwerys, B; Martin, N; Marzan, K; et al. OP0221 EFFICACY OF SECUKINUMAB IN ENTHESITIS-RELATED ARTHRITIS: RESULTS FROM A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TREATMENT WITHDRAWAL, PHASE 3 STUDY (JUNIPERA). Annals of the Rheumatic Diseases. 2022; 81:145-146.

Ruperto, N; Brunner, HI; Posner, HB; Lazariciu, I; Martini, A; Lovell, DJ. Tofacitinib for juvenile idiopathic arthritis - Authors' reply. The Lancet. 2022; 399.

Aljaberi, N; Wenderfer, SE; Mathur, A; Qiu, T; Jose, S; Merritt, A; Rose, J; Devarajan, P; Huang, B; Brunner, H. Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus. Lupus Science and Medicine. 2022; 9.

Hossain, MM; Wilkerson, J; McGrath, JA; Farhadi, PN; Brokamp, C; Khan, MT F; Goldberg, B; Brunner, HI; Macaluso, M; Miller, FW; et al. The Geospatial Distribution of Myositis and Its Phenotypes in the United States and Associations With Roadways: Findings From a National Myositis Patient Registry. Frontiers in Medicine. 2022; 9.

Chalhoub, NE; Wenderfer, SE; Levy, DM; Rouster-Stevens, K; Aggarwal, A; Savani, SI; Ruth, NM; Arkachaisri, T; Qiu, T; Merritt, A; et al. International Consensus for the Dosing of Corticosteroids in Childhood-Onset Systemic Lupus Erythematosus With Proliferative Lupus Nephritis. Arthritis and Rheumatology. 2022; 74:263-273.

Cody, EM; Brunner, HI. Biomarkers in Childhood-Onset Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America. 2022; 48:271-285.

Andrade Balbi, V; Artur Silva, C; Nascimento Pedrosa, T; Maria Rodrigues Pereira, R; Maria de Arruda Campos, L; Pires Leon, E; Duarte, N; Melechco Carvalho, V; Gofinet Pasoto, S; Cordeiro do Rosário, . Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis. Lupus. 2022; 31:97-104.

Balmuri, N; Soulsby, WD; Cooley, V; Gerber, L; Lawson, E; Goodman, S; Onel, K; Mehta, B; Abel, N; Abulaban, K; et al. Community poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis. Pediatric Rheumatology. 2021; 19.

Beukelman, T; Lougee, A; Matsouaka, RA; Collier, D; Rumsey, DG; Schenfeld, J; Stryker, S; Twilt, M; Kimura, Y; Abel, N; et al. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. Pediatric Rheumatology. 2021; 19.

Dave, I; Estroff, B; Gergely, T; Rostad, CA; Ponder, LA; McCracken, C; Prahalad, S; Abel, N; Abulaban, K; Adams, A; et al. Impact of the Season of Birth on the Development of Juvenile Idiopathic Arthritis in the United States: A Nationwide Registry-based Study. Journal of Rheumatology. 2021; 48:1856-1862.

Ruperto, N; Brunner, HI; Synoverska, O; Ting, TV; Mendoza, CA; Spindler, A; Vyzhga, Y; Marzan, K; Grebenkina, L; Tirosh, I; et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. The Lancet. 2021; 398:1984-1996.

van Vollenhoven, RF; Bertsias, G; Doria, A; Isenberg, D; Morand, E; Petri, MA; Pons-Estel, BA; Rahman, A; Ugarte-Gil, MF; Voskuyl, A; et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine. 2021; 8.

Ruperto, N; Brunner, HI; Pacheco-Tena, C; Louw, I; Vega-Cornejo, G; Spindler, AJ; Kingsbury, DJ; Schmeling, H; Borzutzky, A; Cuttica, R; et al. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis. Rheumatology. 2021; 60:4495-4507.

Ruperto, N; Brunner, HI; Ramanan, AV; Horneff, G; Cuttica, R; Henrickson, M; Anton, J; Boteanu, AL; Penades, IC; Minden, K; et al. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis. Rheumatology. 2021; 60:4568-4580.

Schultz, K; Divanovic, A; Towe, C; Miethke, A; Wusik, K; Hammill, A; Brunner, H. Clinicopathologic Conference: A Four-Year-Old Child With Digital Clubbing. Arthritis Care and Research. 2021; 73:1379-1386.

Ong, MS; Ringold, S; Kimura, Y; Schanberg, LE; Tomlinson, GA; Natter, MD; Abel, N; Abulaban, K; Adams, A; Adams, M; et al. Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. Arthritis and Rheumatology. 2021; 73:1910-1920.

Kimura, Y; Schanberg, LE; Tomlinson, GA; Riordan, ME; Dennos, AC; Del Gaizo, V; Murphy, KL; Weiss, PF; Natter, MD; Feldman, BM; et al. Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. Arthritis and Rheumatology. 2021; 73:1898-1909.

Brunner, HI; Abud-Mendoza, C; Mori, M; Pilkington, CA; Syed, R; Takei, S; Viola, DO; Furie, RA; Navarra, S; Zhang, F; et al. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021; 7.

Brunner, HI; Chen, C; Bovis, F; De Benedetti, F; Espada, G; Joos, R; Akikusa, J; Chaitow, J; Boteanu, AL; Kimura, Y; et al. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. Arthritis Care and Research. 2021; 73:1264-1274.

Mannion, ML; Xie, F; Horton, DB; Ringold, S; Correll, CK; Dennos, A; Beukelman, T; Abel, N; Abulaban, K; Adams, A; et al. Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. Journal of Rheumatology. 2021; 48:1322-1329.

Avar-Aydin, PO; Schultz, K; Brunner, HI. Metrics and Outcome Measures of Disease Activity and Damage in Childhood-Onset Systemic Lupus Erythematosus. Outcome Measures and Metrics in Systemic Lupus Erythematosus. 2021.

Lovell, DJ; Brunner, HI. Evolution in the Understanding of Pediatric-Onset Axial Spondyloarthritis. Arthritis Care and Research. 2021; 73:921-923.

Ruperto, N; Brunner, HI; Tzaribachev, N; Vega-Cornejo, G; Louw, I; Cimaz, R; Dare, J; Espada, G; Faugier, E; Ferrandiz, M; et al. Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis. Journal of Rheumatology. 2021; 48:1073-1081.

Cody, EM; Bennett, MR; Gulati, G; Ma, Q; Altaye, M; Devarajan, P; Brunner, HI. Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity. Kidney International Reports. 2021; 6:1949-1960.

Rumsey, DG; Lougee, A; Matsouaka, R; Collier, DH; Schanberg, LE; Schenfeld, J; Shiff, NJ; Stoll, ML; Stryker, S; Weiss, PF; et al. Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. Arthritis Care and Research. 2021; 73:940-946.

Dominguez, D; Kamphuis, S; Beyene, J; Wither, J; Harley, JB; Blanco, I; Vila-Inda, C; Brunner, H; Klein-Gitleman, M; McCurdy, D; et al. Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. Journal of Rheumatology. 2021; 48:852-858.

Aljaberi, N; Nguyen, K; Strahle, C; Merritt, A; Mathur, A; Brunner, HI. Performance of the New 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in Children and Young Adults. Arthritis Care and Research. 2021; 73:580-585.

Lovell, DJ; Huang, B; Chen, C; Angeles-Han, ST; Simon, TA; Brunner, HI. Prevalence of autoimmune diseases and other associated conditions in children and young adults with juvenile idiopathic arthritis. RMD Open. 2021; 7.

Brunner, HI; Ruperto, N; Zuber, Z; Cuttica, R; Keltsev, V; Xavier, RM; Burgos-Vargas, R; Penades, IC; Silverman, ED; Espada, G; et al. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. Arthritis and Rheumatology. 2021; 73:530-541.

Quartier, P; Alexeeva, E; Constantin, T; Chasnyk, V; Wulffraat, N; Palmblad, K; I. Brunner, H; Marzan, K; Schneider, R; Horneff, G; et al. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study. Arthritis and Rheumatology. 2021; 73:336-346.

Reighard, SD; Krishnamurthy, D; Cevik, H; Ochayon, DE; Ali, A; Seelamneni, H; Brunner, HI; Waggoner, SN. Immunomodulatory effects of cytokine-induced expansion of cytotoxic lymphocytes in a mouse model of lupus-like disease. Cytotherapy. 2021; 23:37-45.

Chen, Y; Sun, L; Xu, H; Dong, M; Mizuno, T; Vinks, AA; Brunner, HI; Li, Y; Li, Z. PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. Frontiers in Pharmacology. 2020; 11.

Aljaberi, N; Tronconi, E; Schulert, G; Grom, AA; Lovell, DJ; Huggins, JL; Henrickson, M; Brunner, HI. The use of S100 proteins testing in juvenile idiopathic arthritis and autoinflammatory diseases in a pediatric clinical setting: a retrospective analysis. Pediatric Rheumatology. 2020; 18.

Brunner, HI; Tzaribachev, N; Cornejo, GV; Joos, R; Gervais, E; Cimaz, R; Calvo Penades, I; Cuttica, R; Lutz, T; Quartier, P; et al. Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept. Pediatric Rheumatology. 2020; 18.

DiFrancesco, MW; Lee, G; Altaye, M; Beebe, DW; Meyers-Eaton, J; Brunner, HI. Cerebral microvascular and microstructural integrity is regionally altered in patients with systemic lupus erythematosus. Arthritis Research and Therapy. 2020; 22.

Simon, TA; Harikrishnan, GP; Kawabata, H; Singhal, S; Brunner, HI; Lovell, DJ. Prevalence of co-existing autoimmune disease in juvenile idiopathic arthritis: a cross-sectional study. Pediatric Rheumatology. 2020; 18.

Brunner, HI; Quartier, P; Alexeeva, E; Constantin, T; Koné-Paut, I; Marzan, K; Schneider, R; Wulffraat, NM; Chasnyk, V; Tirosh, I; et al. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. Arthritis and Rheumatology. 2020; 72:2147-2158.

Malattia, C; Ruperto, N; Pederzoli, S; Palmisani, E; Pistorio, A; Wouters, C; Dolezalova, P; Flato, B; Garay, S; Giancane, G; et al. Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials. Arthritis Research and Therapy. 2020; 22.

Brunner, HI; Wong, R; Nys, M; Kou, TD; Dominique, A; Martini, A; Lovell, DJ; Ruperto, N. Abatacept: A Review of the Treatment of Polyarticular-Course Juvenile Idiopathic Arthritis. Paediatric Drugs. 2020; 22:653-672.

Parks, CG; Wilkerson, J; Rose, KM; Faiq, A; Noroozi Farhadi, P; Long, CS; Bayat, N; Brunner, HI; Goldberg, B; McGrath, JA; et al. Association of Ultraviolet Radiation Exposure With Dermatomyositis in a National Myositis Patient Registry. Arthritis Care and Research. 2020; 72:1636-1644.

Brunner, HI; Nanda, K; Toth, M; Foeldvari, I; Bohnsack, J; Milojevic, D; Rabinovich, CE; Kingsbury, DJ; Marzan, K; Chalom, E; et al. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results. Arthritis Care and Research. 2020; 72:1420-1430.

Smitherman, EA; Huang, B; Furnier, A; Taylor, J; Burns, MB; Brunner, HI; Morgan, EM. Quality of Care in Childhood-onset Systemic Lupus Erythematosus: Report of an Intervention to Improve Cardiovascular and Bone Health Screening. Journal of Rheumatology. 2020; 47:1506-1513.

Brunner, HI; Abud-Mendoza, C; Viola, DO; Calvo Penades, I; Levy, D; Anton, J; Calderon, JE; Chasnyk, VG; Ferrandiz, MA; Keltsev, V; et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Annals of the Rheumatic Diseases. 2020; 79:1340-1348.

Canna, SW; Schulert, GS; de Jesus, A; Pickering, A; Brunner, H; Gadina, M; Levine, S; Goldbach-Mansky, R; Boutelle, J; Sinha, R; et al. Proceedings from the 2nd Next Gen Therapies for Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome symposium held on October 3-4, 2019. Pediatric Rheumatology. 2020; 18.

Lovell, DJ; Brunner, HI; Reiff, AO; Jung, L; Jarosova, K; Nemcova, D; Mouy, R; Sandborg, C; Bohnsack, JF; Elewaut, D; et al. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. RMD Open. 2020; 6.

Reighard, SD; Cranert, SA; Rangel, KM; Ali, A; Gyurova, IE; de la Cruz-Lynch, AT; Tuazon, JA; Khodoun, MV; Kottyan, LC; Smith, DF; et al. Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells. 2020; 1.

Huang, B; Qiu, T; Chen, C; Zhang, Y; Seid, M; Lovell, D; Brunner, HI; Morgan, EM; PCATS, . Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis. RMD Open. 2020; 6.

Huang, B; Qiu, T; Chen, C; Neace, A; Zhang, Y; Yue, X; Zahner, J; Adams, M; Seid, M; Lovell, D; et al. Comparative Effectiveness Research Using Electronic Health Records Data: Ensure Data Quality. . : SAGE Publications Ltd; SAGE Publications Ltd; 2020.

Cunningham, NR; Fussner, LM; Moorman, E; Aydin, PO A; Brunner, HI; Kashikar-Zuck, S. Development and pilot testing of the treatment and education approach for childhood-onset lupus (TEACH): a cognitive behavioral treatment. Pediatric Rheumatology. 2019; 17.

Leong, JY; Chen, P; Yeo, JG; Ally, F; Chua, C; Hazirah, SN; Poh, SL; Pan, L; Lai, L; Lee, ES C; et al. Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal. Annals of the Rheumatic Diseases. 2019; 78:1712-1721.

Schulert, GS; Yasin, S; Carey, B; Chalk, C; Do, T; Schapiro, AH; Husami, A; Watts, A; Brunner, HI; Huggins, J; et al. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors. Arthritis and Rheumatology. 2019; 71:1943-1954.

Deng, J; Chalhoub, NE; Sherwin, CM; Li, C; Brunner, HI. Glucocorticoids pharmacology and their application in the treatment of childhood-onset systemic lupus erythematosus. Seminars in Arthritis and Rheumatism. 2019; 49:251-259.

Pardeo, M; Wang, J; Ruperto, N; Alexeeva, E; Chasnyk, V; Schneider, R; Horneff, G; Huppertz, H; Minden, K; Onel, K; et al. Neutropenia During Tocilizumab Treatment Is Not Associated with Infection Risk in Systemic or Polyarticular-course Juvenile Idiopathic Arthritis. Journal of Rheumatology. 2019; 46:1117-1126.

Rodriguez-Smith, J; Brunner, HI. Update on the treatment and outcome of systemic lupus erythematous in children. Current Opinion in Rheumatology. 2019; 31:464-470.

Morgan, EM; Munro, JE; Horonjeff, J; Horgan, B; Shea, B; Feldman, BM; Clairman, H; III, BC O; Thornhill, S; Strand, V; et al. Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. Journal of Rheumatology. 2019; 46:1006-1013.

Mulvihill, E; Ardoin, S; Thompson, SD; Zhou, B; Yu, GR; King, E; Singer, N; Levy, DM; Brunner, H; Wu, YL; et al. Elevated serum complement levels and higher gene copy number of complement C4B are associated with hypertension and effective response to statin therapy in childhood-onset systemic lupus erythematosus (SLE). Lupus Science and Medicine. 2019; 6.

Brunner, HI; Holland, MJ; Beresford, MW; Ardoin, SP; Appenzeller, S; Silva, CA; Flores, F; Aydin, PO A; Wenderfer, SE; Levy, DM; et al. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus. Arthritis Care and Research. 2019; 71:579-590.

Aljaberi, N; Bennett, M; Brunner, HI; Devarajan, P. Proteomic profiling of urine: implications for lupus nephritis. Expert Review of Proteomics. 2019; 16:303-313.

Angeles-Han, ST; Lo, MS; Henderson, LA; Lerman, MA; Abramson, L; Coopers, AM; Parsa, MF; Zemel, LS; Ronis, T; Beukelman, T; et al. Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. Arthritis Care and Research. 2019; 71:482-491.

Ramanan, AV; Brunner, HI; Ruperto, N; Martini, A; Cuttica, RJ; Weiss, JE; Henrickson, M; Schmeling, H; Antón, J; Minden, K; et al. 170 Safety and efficacy of subcutaneous tocilizumab in patients with systemic and polyarticular juvenile idiopathic arthritis. Rheumatology. 2019; 58.

Hinze, CH; Foell, D; Johnson, AL; Spalding, SJ; Gottlieb, BS; Morris, PW; Kimura, Y; Onel, K; Li, SC; Grom, AA; et al. Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. Arthritis and Rheumatology. 2019; 71:451-459.

Brunner, HI; Martini, A; Lovell, DJ; Ruperto, N; Or, PR I T; Collaborative, PR. Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities. Annals of the Rheumatic Diseases. 2019; 78:162-170.

Turnier, JL; Brunner, HI; Bennett, M; Aleed, A; Gulati, G; Haffey, WD; Thornton, S; Wagner, M; Devarajan, P; Witte, D; et al. Discovery of SERPINA3 as a candidate urinary biomarker of lupus nephritis activity. Rheumatology. 2019; 58:321-330.

Brunner, HI; Gulati, G; Klein-Gitelman, MS; Rouster-Stevens, KA; Tucker, L; Ardoin, SP; Onel, KB; Mainville, R; Turnier, J; Aydin, PO A; et al. Urine biomarkers of chronic kidney damage and renal functional decline in childhood-onset systemic lupus erythematosus. Pediatric Nephrology. 2019; 34:117-128.

Contact Us

Hermine I. Brunner, MD, MSc, MBA
Professor, UC Department of Pediatrics

Phone: 513-636-4676
Email: hermine.brunner@cchmc.org